Analysts Expect CounterPath Corporation (CPAH) to Post $0.02 Earnings Per Share

Shares of CounterPath Corporation (NASDAQ:CPAH) (TSE:CCV) have received a consensus broker rating score of 2.00 (Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation.

Brokers have set a 12 month consensus price objective of $4.49 for the company and are anticipating that the company will post $0.02 EPS for the current quarter, according to Zacks. Zacks has also assigned CounterPath an industry rank of 162 out of 265 based on the ratings given to related companies.

Several research firms recently commented on CPAH. ValuEngine lowered CounterPath from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research upgraded CounterPath from a “sell” rating to a “hold” rating in a research note on Wednesday, September 13th.

CounterPath (NASDAQ:CPAH) traded down $0.23 during trading on Friday, reaching $2.66. The company had a trading volume of 257,184 shares, compared to its average volume of 362,884. CounterPath has a 52-week low of $1.75 and a 52-week high of $6.79.

TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/17/analysts-expect-counterpath-corporation-cpah-to-post-0-02-earnings-per-share.html.

CounterPath Company Profile

CounterPath Corporation designs, develops and sells software and services that enable enterprises and telecommunication service providers to deliver unified communications (UC) services, including voice, video, messaging and collaboration functionality, over their Internet Protocol (IP)-based networks.

Get a free copy of the Zacks research report on CounterPath (CPAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about CounterPath? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CounterPath and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit